{"id":42271,"date":"2021-07-08T11:14:51","date_gmt":"2021-07-08T07:14:51","guid":{"rendered":"https:\/\/fedai.az\/?p=42271"},"modified":"2021-07-08T12:17:32","modified_gmt":"2021-07-08T08:17:32","slug":"sosial-maarifl%c9%99ndirm%c9%99-arsinla-olcul%c9%99n-%c9%99lillik-meyarlarini-t%c9%99qdim-edirik-2","status":"publish","type":"post","link":"https:\/\/fedai.az\/?p=42271","title":{"rendered":"SOS\u0130AL MAAR\u0130FL\u018fND\u0130RM\u018f: \u00abAr\u015f\u0131nla \u00f6l\u00e7\u00fcl\u0259n \u0259lillik meyarlar\u0131\u00bbn\u0131 t\u0259qdim edirik"},"content":{"rendered":"\n

Bu i\u015fi \u018fm\u0259k v\u0259 \u0259halinin sosial m\u00fcdafi\u0259si nazirliyi g\u00f6rm\u0259liydi. Sosial maarifl\u0259ndirm\u0259 rubrikas\u0131 il\u0259 30 il m\u00fcharib\u0259 aparm\u0131\u015f \u00f6lk\u0259d\u0259 \u0259lilliyin t\u0259yinat\u0131yla ba\u011fl\u0131 \u00abm\u00fcharib\u0259\u00bb ad\u0131n\u0131n \u00e7\u0259kilm\u0259m\u0259si \u00e7ox ilginc bir m\u0259s\u0259l\u0259dir v\u0259 r\u0259smi olaraq haql\u0131 naraz\u0131l\u0131\u011fa s\u0259b\u0259b olan oyunlar\u0131 v\u0259 h\u0259tta bu Qanunun layih\u0259sini, h\u0259m Milli M\u0259clisin sosial siyas\u0259t komit\u0259si, h\u0259m d\u0259 nazirlik a\u00e7\u0131q m\u0259tnl\u0259 \u00f6lk\u0259 Prezidentinin ad\u0131yla ba\u011flay\u0131rlar.<\/strong><\/p>\n\n\n\n

Q\u0259bul edilmi\u015f m\u00fcdd\u0259alar\u0131 t\u0259qdim edirik:<\/strong><\/p>\n\n\n\n

\u018fvv\u0259li: <\/span><\/strong>https:\/\/fedai.az\/?p=42201&fbclid=IwAR0N2XAlE2FHxnAcCxgOw7OXRVseIpmKwwh6RT95y0rxJUKUquS7JEb5SqQ<\/a><\/p>\n\n\n\n

3. H\u0259zm orqanlar\u0131n\u0131n x\u0259st\u0259likl\u0259ri (K00-K93) 3-c\u00fc b\u0259nd\u0259 dair qeyd: \u0130nsan orqanizminin h\u0259zm orqanlar\u0131n\u0131n x\u0259st\u0259likl\u0259rd\u0259n, travma v\u0259 ya \u00e7at\u0131\u015fmazl\u0131qlardan ir\u0259li g\u0259l\u0259n davaml\u0131 funksional pozuntular\u0131n\u0131n a\u011f\u0131rl\u0131q d\u0259r\u0259c\u0259sinin k\u0259miyy\u0259tc\u0259 qiym\u0259tl\u0259ndirilm\u0259si h\u0259zm etm\u0259 funksiyas\u0131n\u0131n pozulmas\u0131 d\u0259r\u0259c\u0259sinin qiym\u0259tl\u0259ndirilm\u0259sin\u0259 \u0259saslan\u0131r. (z\u00fclal-enerji \u00e7at\u0131\u015fmazl\u0131\u011f\u0131). Patoloji prosesin dig\u0259r amill\u0259ri d\u0259 n\u0259z\u0259r\u0259 al\u0131n\u0131r: gedi\u015fat\u0131n formas\u0131 v\u0259 a\u011f\u0131rl\u0131\u011f\u0131, prosesin aktivliyi, k\u0259skinl\u0259\u015fm\u0259l\u0259rin olmas\u0131 v\u0259 tezliyi, patoloji prosesin yay\u0131lmas\u0131, h\u0259d\u0259f orqanlar\u0131n qo\u015fulmas\u0131, immunitetin azald\u0131lmas\u0131na ehtiyac, f\u0259sadlar\u0131n olmas\u0131. 3.1 A\u011f\u0131z bo\u015flu\u011fu, a\u011f\u0131z suyu v\u0259zil\u0259ri v\u0259 \u00e7\u0259n\u0259 x\u0259st\u0259likl\u0259ri K00-K14 <\/p>\n\n\n\n

3.1.1 \u00dcz \u00e7\u0259n\u0259 anomaliyalar\u0131 (damaq, dodaq, \u00e7\u0259n\u0259 \u00e7at\u0131\u015fmazl\u0131qlar\u0131; kontrakturalar) K07-K10 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

3.1.1.1 Nitq (artikulyasiya) \u00e7at\u0131\u015fmazl\u0131qlar\u0131 il\u0259 s\u0259ciyy\u0259l\u0259n\u0259n, maye halda v\u0259 ya \u0259zilmi\u015f qida q\u0259bulu z\u0259rur\u0259tini yaradan \u00e7\u0259n\u0259 kontrakturas\u0131 40 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

3.1.1.2 \u00c7eyn\u0259m\u0259 v\u0259 artikulyasiya funksiyas\u0131n\u0131n \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 pozulmas\u0131 hal\u0131nda alt \u00e7\u0259n\u0259nin bir hiss\u0259sinin itirilm\u0259si 40 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

3.1.1.3 \u00dcst \u00e7\u0259n\u0259nin bir hiss\u0259sinin itirilm\u0259si, eyb\u0259c\u0259rl\u0259\u015fdir\u0259n \u00e7at\u0131\u015fmazl\u0131qlar, burunun strukturunun v\u0259 \u00fcst \u00e7\u0259n\u0259 bo\u015fluqlar\u0131n\u0131n \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 pozulmas\u0131 il\u0259 40 M\u00fcdd\u0259tsiz<\/p>\n\n\n\n

3.1.1.4 Dama\u011f\u0131n \u0259h\u0259miyy\u0259tli \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, \u00e7at\u0131\u015fmazl\u0131q protezi il\u0259 35 1il <\/p>\n\n\n\n

3.1.1.5 Qida q\u0259bulu v\u0259 nitq \u00e7at\u0131\u015fmazl\u0131\u011f\u0131na s\u0259b\u0259b olan v\u0259 protezl\u0259 b\u0259rpas\u0131 m\u00fcmk\u00fcn olmayan dama\u011f\u0131n itirilm\u0259si hal\u0131 40 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

3.1.1.6 M\u00fcalic\u0259 bit\u0259n\u0259 q\u0259d\u0259r u\u015faqlarda dodaq, \u00e7\u0259n\u0259, s\u0259rt damaq v\u0259 yum\u015faq damaq yar\u0131qlar\u0131 30 1 il <\/p>\n\n\n\n

3.1.1.7 Yar\u0131\u011f\u0131n ba\u011flanmas\u0131na q\u0259d\u0259r u\u015faqlarda dodaq, \u00e7\u0259n\u0259, s\u0259rt damaq v\u0259 yum\u015faq damaq yar\u0131qlar\u0131 20 1 il <\/p>\n\n\n\n

3.1.1.8 Birinci kurs m\u00fcalic\u0259nin sonuna q\u0259d\u0259r doda\u011f\u0131n v\u0259 dama\u011f\u0131n tam yar\u0131\u011f\u0131 (\u0259m\u0259liyyatdan bir il sonra) bununla \u0259laq\u0259li olan e\u015fitm\u0259nin m\u00fcnt\u0259z\u0259m pozulmas\u0131n\u0131n (e\u015fitm\u0259 borusunun havaland\u0131rma funksiyas\u0131n\u0131n pozulmas\u0131) v\u0259 burun t\u0259n\u0259ff\u00fcs\u00fcn\u00fcn pozulmas\u0131n\u0131n n\u0259z\u0259r\u0259 al\u0131nmas\u0131 il\u0259 30 1 il <\/p>\n\n\n\n

3.1.1.9 Yar\u0131\u011f\u0131n ba\u011flanmas\u0131na q\u0259d\u0259r doda\u011f\u0131n v\u0259 dama\u011f\u0131n tam yar\u0131\u011f\u0131 20 1 ilSiyas\u0259t 20.06.2021\u0130nsan orqanizminin funksiyalar\u0131n\u0131n sabit pozuntular\u0131n\u0131n t\u0259zah\u00fcr d\u0259r\u0259c\u0259sinin k\u0259miyy\u0259tc\u0259 qiym\u0259tl\u0259ndirilm\u0259siYay\u0131mlad\u0131: Admin EditInsan-orqanizminin-funksiyalarinin-sabit-pozuntularinin-t\u0259zahur-d\u0259r\u0259c\u0259sinin-k\u0259miyy\u0259tc\u0259-qiym\u0259tl\u0259ndirilm\u0259si\u0421\u043a\u0430\u0447\u0430\u0442\u044c 1 7 Az\u0259rbaycan Respublikas\u0131 Nazirl\u0259r Kabinetinin 2019-cu il __ ___ tarixli __ n\u00f6mr\u0259li q\u0259rar\u0131 il\u0259 t\u0259sdiq edilmi\u015f «\u018flilliyin m\u00fc\u0259yy\u0259n olunmas\u0131 meyarlar\u0131»na \u018flav\u0259 \u0130nsan orqanizminin funksiyalar\u0131n\u0131n sabit pozuntular\u0131n\u0131n t\u0259zah\u00fcr d\u0259r\u0259c\u0259sinin k\u0259miyy\u0259tc\u0259 qiym\u0259tl\u0259ndirilm\u0259si B\u0259nd N- si X\u0259st\u0259likl\u0259rin , travmalar\u0131n v\u0259 ya \u00e7at\u0131\u015fmazl\u0131qlar\u0131n v\u0259 onlar\u0131n n\u0259tic\u0259l\u0259rinin ad\u0131, orqanizmin funksiyalar\u0131n\u0131n davaml\u0131 pozulmas\u0131n\u0131n kliniki funksional x\u00fcsusiyy\u0259tl\u0259ri XBT-10 (kod) Faizl\u0259 qiym\u0259t-l\u0259ndirm\u0259 M\u00fcdd\u0259t 1. T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n x\u0259st\u0259likl\u0259ri. T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n x\u0259st\u0259likl\u0259ri n\u0259tic\u0259sind\u0259 dig\u0259r orqanlar\u0131n z\u0259d\u0259l\u0259nm\u0259l\u0259ri il\u0259 ke\u00e7\u0259n patalogiyalar (J00-J99) 1-ci b\u0259nd\u0259 dair qeyd: Tibbi-sosial ekspertiza zaman\u0131 x\u0259st\u0259likl\u0259r, travma n\u0259tic\u0259sind\u0259 v\u0259 ya \u00e7at\u0131\u015fmazl\u0131qlar s\u0259b\u0259bind\u0259n orqanizmin t\u0259n\u0259ff\u00fcs funksiyas\u0131n\u0131n pozulmas\u0131n\u0131n a\u011f\u0131rl\u0131q d\u0259r\u0259c\u0259sinin k\u0259miyy\u0259t qiym\u0259tl\u0259ndirilm\u0259si, \u0259sas\u0259n x\u0259st\u0259likl\u0259r, travma n\u0259tic\u0259l\u0259rind\u0259 v\u0259 ya \u00e7at\u0131\u015fmazl\u0131qlar s\u0259b\u0259bind\u0259n \u0259m\u0259l\u0259 g\u0259lmi\u015f t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n a\u011f\u0131rl\u0131q d\u0259r\u0259c\u0259sinin m\u00fc\u0259yy\u0259n edilm\u0259sin\u0259 \u0259saslan\u0131r. Eyni zamanda patoloji prosesin dig\u0259r amill\u0259ri d\u0259 n\u0259z\u0259r\u0259 al\u0131n\u0131r: gedi\u015fat\u0131n formas\u0131 v\u0259 a\u011f\u0131rl\u0131\u011f\u0131, prosesin aktivliyi, k\u0259skinl\u0259\u015fm\u0259l\u0259rinin m\u00f6vcudlu\u011fu v\u0259 tezliyi, onlar\u0131n olmas\u0131 zaman\u0131 paroksizml \u0259rin olmas\u0131 v\u0259 tezliyi, patoloji prosesin yay\u0131lmas\u0131, h\u0259d\u0259f orqanlar\u0131n\u0131n qo\u015fulmas\u0131, immunitetin azald\u0131lmas\u0131na ehtiyac v\u0259 f\u0259sadla\u015fmalar\u0131n m\u00f6vcudlu\u011fu. <\/p>\n\n\n\n

1.1 A\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131n\u0131n xroniki x\u0259st\u0259likl\u0259ri J40-J47<\/p>\n\n\n\n

1.1.1 Sad\u0259 v\u0259 selikli-irinli xroniki bronxit J41 Sad\u0259 xroniki bronxit J41.0 Selikli-irinli xroniki bronxit J41.1 Qar\u0131\u015f\u0131q, sad\u0259 v\u0259 selikli-irinli xroniki bronxit J41.8 D\u0259qiql\u0259\u015fdirilm\u0259mi\u015f xroniki bronxit J42 8 Emfizema J43 Dig\u0259r xroniki obstruktiv a\u011fciy\u0259r x\u0259st\u0259liyi J44 A\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131n\u0131n k\u0259skin respirator infeksiyas\u0131 il\u0259 birg\u0259 m\u00fc\u015fahid\u0259 olunan a\u011fciy\u0259rin xroniki obstruktiv x\u0259st\u0259liyinin J44.0 A\u011fciy\u0259rin d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f, k\u0259skinl\u0259\u015fm\u0259 il\u0259 m\u00fc\u015fahid\u0259 olunan xroniki obstruktiv x\u0259st\u0259liyi J44.1 A\u011fciy\u0259rin dig\u0259r d\u0259qiql\u0259\u015fdirilmi\u015f xroniki obstruktiv x\u0259st\u0259liyi J44.8 A\u011fciy\u0259rin d\u0259qiq\u0259l\u0259\u015fdirilm\u0259mi\u015f xroniki obstruktiv x\u0259st\u0259liyi J44.9 Bronxoektaziya x\u0259st\u0259liyi J47 Xarici amill\u0259rin t\u0259sirind\u0259n yaranan a\u011fciy\u0259r x\u0259st\u0259likl\u0259ri J60-J70 \u018fsas\u0259n interstisial toxuman\u0131n z\u0259d\u0259l\u0259nm\u0259si il\u0259 m\u00fc\u015fahid\u0259 olunan dig\u0259r respirator x\u0259st\u0259likl\u0259r J80-J84 A\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131n\u0131n irinli v\u0259 nekrotik hallar\u0131 J85-J86 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n dig\u0259r x\u0259st\u0259likl\u0259ri J95-J99 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.1.1 Y\u00fcng\u00fcl forma, nadir k\u0259skinl\u0259\u015fm\u0259l\u0259rl\u0259 (ild\u0259 2-3 d\u0259f\u0259), xroniki t\u0259n\u0259fff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olmadan k\u0259skinl\u0259\u015fm\u0259 zaman\u0131 bronxial obstruksiya il\u0259 10 1 il <\/p>\n\n\n\n

1.1.1.2 Orta a\u011f\u0131r forma, d\u00f6vr\u00fc q\u0131sa k\u0259skinl\u0259\u015fm\u0259l\u0259rl\u0259 (ild\u0259 4-6 d\u0259f\u0259), k\u0259skinl\u0259m\u0259 zaman\u0131 bronxial obstruksia v\u0259 a\u011f ciy\u0259r emfizemas\u0131 il\u0259, 0-I d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 20-30 1 il <\/p>\n\n\n\n

1.1.1.3 T\u0259ng\u0259n\u0259f\u0259slik simptomlar\u0131n\u0131n g\u00fccl\u0259nm\u0259si, qeyd olunan d\u00f6vr\u00fc k\u0259skinl\u0259\u015fm\u0259l\u0259rl\u0259 orta a\u011f\u0131r forma (ild\u0259 4-6 d\u0259f\u0259), hipoksemik xroniki respirator \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 I-II d\u0259r\u0259c\u0259 31-60 1 il <\/p>\n\n\n\n

1.1.1.4 T\u0259ng\u0259n\u0259f\u0259sliyin artmas\u0131 qeyd edil\u0259n tez-tez k\u0259skinl\u0259\u015fm\u0259l\u0259ri olan a\u011f\u0131r forma (k\u0259skinl\u0259\u015fm\u0259l\u0259r ild\u0259 6 d\u0259f\u0259d\u0259n \u00e7ox), hipoksemik v\u0259 hiperkapnik xroniki respirator \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, II v\u0259 III d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131; IIA d\u0259r\u0259c\u0259li xroniki a\u011f ciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 61-80 2 il <\/p>\n\n\n\n

1.1.1.5 A\u011f\u0131r forma, davaml\u0131 residivl\u0259\u015f\u0259n gedi\u015fat, daimi a\u011f\u0131r t\u0259ng\u0259n\u0259f\u0259slikl\u0259r, hiperkapniya, xroniki respirator hipoksemiya, xroniki respirator alkaloz, II-III d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, xroniki a\u011f ciy\u0259r \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 IIB v\u0259 III d\u0259r\u0259c\u0259 81-100 M\u00fcdd\u0259tsiz Qeyd Bronxoektoziya x\u0259st\u0259liyi, emfizema v\u0259 a\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131n\u0131n irinli v\u0259 nekrotik hallar\u0131 zaman\u0131 c\u0259rrahi m\u00fcalic\u0259 \u00fcsullar\u0131ndan istifad\u0259 edilmi\u015fs\u0259 onun n\u0259tic\u0259l\u0259ri n\u0259z\u0259r\u0259 al\u0131n\u0131r 1.1.2 Astma J45 Allergik komponentin \u00fcst\u00fcnl\u00fcy\u00fc il\u0259 m\u00fc\u015fahid\u0259 olunan astma J45.0 Qeyri-allergik astma J45.1 Qar\u0131\u015f\u0131q astma J45.8 D\u0259qiql\u0259\u015fdirilm\u0259mi\u015f astma J45.9 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.2.1 Y\u00fcng\u00fcl v\u0259 orta a\u011f\u0131r gedi\u015fli — nadir (ild\u0259 2-3 d\u0259f\u0259) m\u00f6vs\u00fcmi k\u0259skinl\u0259\u015fm\u0259l\u0259r v\u0259\/v\u0259 ya y\u00fcng\u00fcl tutmalarla (n\u0259zar\u0259t olunan, y\u00fcng\u00fcl v\u0259 ya orta a\u011f\u0131r olan persist\u0259 ed\u0259n bronxial astma): 0-1 d\u0259r\u0259c\u0259li xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 10-30 1il <\/p>\n\n\n\n

1.1.2.2 Orta a\u011f\u0131r gedi\u015fli — m\u00fclayim tez-tez k\u0259skinl\u0259\u015fm\u0259l\u0259r (ild\u0259 3-6 d\u0259f\u0259) v\u0259 orta a\u011f\u0131r tutmalarla (qism\u0259n n\u0259zar\u0259t olunan, orta a\u011f\u0131r olan persist\u0259 ed\u0259n bronxial astma) I-II d\u0259r\u0259c\u0259li xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 31-60 1il <\/p>\n\n\n\n

1.1.2.3 A\u011f\u0131r gedi\u015fli — tez-tez ba\u015f ver\u0259n k\u0259skinl\u0259\u015fm\u0259l\u0259r (ild\u0259 6 d\u0259f\u0259d\u0259n art\u0131q) v\u0259 a\u011f\u0131r tutmalarla (n\u0259zar\u0259t olunmayan, a\u011f\u0131r persist\u0259 ed\u0259n bronxial astma) II-III d\u0259r\u0259c\u0259li xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 IIA m\u0259rh\u0259l\u0259d\u0259 xroniki a\u011f ciy\u0259r-\u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 61-80 1 il <\/p>\n\n\n\n

1.1.2.4 A\u011f\u0131r gedi\u015fli — tez-tez ba\u015f ver\u0259n k\u0259skinl\u0259\u015fm\u0259l\u0259r (ild\u0259 6 d\u0259f\u0259d\u0259n art\u0131q) v\u0259 a\u011f\u0131r tutmalarla (n\u0259zar\u0259t olunmayan, a\u011f\u0131r persist\u0259 ed\u0259n bronxial astma) III d\u0259r\u0259c\u0259li xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 IIB, III m\u0259rh\u0259l\u0259d\u0259 xroniki a\u011f ciy\u0259r-\u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 81-100 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

1.1.3 U\u015faqlarda a\u015fa\u011f\u0131 t\u0259n\u0259ff\u00fcs yollar\u0131n\u0131n xroniki x\u0259st\u0259liyi il\u0259 m\u00fc\u015fahid\u0259 olunan bronxial astma J45 J40-J47 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.3.1 N\u0259zar\u0259t olunan y\u00fcng\u00fcl gedi\u015fli, nadir ba\u015f ver\u0259n (ild\u0259 2-3 d\u0259f\u0259) m\u00f6vs\u00fcmi k\u0259skinl\u0259\u015fm\u0259l\u0259r v\u0259\/v\u0259 ya y\u00fcng\u00fcl tutmalarla, xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 olmadan; bronxit, ild\u0259 6 h\u0259ft\u0259d\u0259n \u00e7ox olmamaq \u015f\u0259rti il\u0259 10-30 1 il<\/p>\n\n\n\n

1.1.3.2 Orta a\u011f\u0131r qism\u0259n n\u0259zar\u0259t olunan v\u0259 daha tez-tez ba\u015f ver\u0259n (ild\u0259 3-4 d\u0259f\u0259) v\u0259\/v\u0259 ya stasionar m\u00fcalic\u0259 t\u0259l\u0259b ed\u0259n a\u011f\u0131r tutmalarla, I-II d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, ild\u0259 2-3 ay davam ed\u0259n uzun m\u00fcdd\u0259t davam ed\u0259n broxit 31-60 1 il <\/p>\n\n\n\n

1.1.3.3 Stasionar m\u00fcalic\u0259 t\u0259l\u0259b ed\u0259n, II d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan tez-tez t\u0259krarlanan (ild\u0259 4 d\u0259f\u0259d\u0259n \u00e7ox) silsil\u0259 a\u011f\u0131r tutmalarla n\u0259zar\u0259t olunmayan a\u011f\u0131r gedi\u015fli, ild\u0259 3 aydan \u00e7ox \u00e7\u0259k\u0259n davaml\u0131 bronxit 61-80 2 il<\/p>\n\n\n\n

1.1.4 A\u011f ciy\u0259r k\u00f6\u00e7\u00fcr\u00fclm\u0259si Z94.2 Qiym\u0259tl\u0259ndirm\u0259 1.1.4.1 K\u00f6\u00e7\u00fcr\u00fclm\u00fc\u015f a\u011f ciy\u0259rin ilk 2 il \u0259rzind\u0259ki v\u0259ziyy\u0259ti 100 2 il<\/p>\n\n\n\n

1.1.4.2 \u0130mmunitetin z\u0259ifl\u0259dilm\u0259si v\u0259\/v\u0259 ya dig\u0259r m\u00fcalic\u0259 v\u0259 b\u0259rpa t\u0259dbirl\u0259rinin apr\u0131lmas\u0131 ehtiyac\u0131 oldu\u011fu halda k\u00f6\u00e7\u00fcr\u00fclm\u00fc\u015f a\u011f ciy\u0259r\u0131n 2 illik m\u00fc\u015fahid\u0259d\u0259n sonrak\u0131 v\u0259ziyy\u0259ti 70-80 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

1.1.4.3 \u0130mmunitetin z\u0259ifl\u0259dilm\u0259si ehtiyac\u0131 oldu\u011fu halda \u0259m\u0259l\u0259 g\u0259lmi\u015f II v\u0259 III d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259\/v\u0259 ya dig\u0259r sisteml\u0259rin (m\u0259s\u0259l\u0259n, \u00fcr\u0259k-damar) a\u011f\u0131r z\u0259d\u0259l\u0259nm\u0259si il\u0259 m\u00fc\u015fayi\u0259t olunan k\u00f6\u00e7\u00fcr\u00fclm\u00fc\u015f a\u011f ciy\u0259r\u0131n 2 illik m\u00fc\u015fahid\u0259d\u0259n sonrak\u0131 v\u0259ziyy\u0259ti 90-100 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

1.1.5 Sarkoidoz D86 A\u011f ciy\u0259r sarkoidozu D86.0 Limfa d\u00fcy\u00fcnl\u0259rinin sarkoidozu il\u0259 birg\u0259 m\u00fc\u015fahid\u0259 olunan a\u011f ciy\u0259r sarkoidozu D86.2 11 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.5.1 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n funksiyas\u0131n\u0131n \u0259h\u0259miyy\u0259tsiz (0-I d\u0259r\u0259c\u0259) pozuntusu — a\u011f ciy\u0259r sarkoidozu v\u0259 ya limfa d\u00fcy\u00fcnl\u0259ri sarkoidozu il\u0259 a\u011f ciy\u0259r sarkoidozu II d\u0259r\u0259c\u0259, f\u0259al m\u0259rh\u0259l\u0259, 0-I d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 10-30 1 il <\/p>\n\n\n\n

1.1.5.2 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n funksiyas\u0131n\u0131n m\u00fclayim (II) d\u0259r\u0259c\u0259 pozuntusu — a\u011f ciy\u0259r sarkoidozu v\u0259 ya limfa d\u00fcy\u00fcnl\u0259ri sarkoidozu il\u0259 a\u011f ciy\u0259r sarkoidozu III d\u0259r\u0259c\u0259, f\u0259al m\u0259rh\u0259l\u0259, II d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 40-60 1 il <\/p>\n\n\n\n

1.1.5.3 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n funksiyas\u0131n\u0131n a\u011f\u0131r (III) d\u0259r\u0259c\u0259 pozuntusu — a\u011f ciy\u0259r sarkoidozu v\u0259 ya limfa d\u00fcy\u00fcnl\u0259ri sarkoidozu il\u0259 a\u011f ciy\u0259r sarkoidozu III d\u0259r\u0259c\u0259, f\u0259al m\u0259rh\u0259l\u0259, f\u0259sadla\u015fmalar v\u0259\/v\u0259 ya dig\u0259r orqanlar\u0131n kombin\u0259 edilmi\u015f z\u0259d\u0259l\u0259nm\u0259l\u0259ri il\u0259, III d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 81-100 2 il <\/p>\n\n\n\n

1.1.6 A\u011f ciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 \u0259lam\u0259tl\u0259ri il\u0259 m\u00fc\u015fayi\u0259t olunan a\u011f ciy\u0259r toxumas\u0131nda kistoz fibroz d\u0259yi\u015fiklik E84.0 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.6.1 Y\u00fcng\u00fcl d\u0259r\u0259c\u0259li klinik t\u0259zah\u00fcr, 0-I d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 10-30 1 il <\/p>\n\n\n\n

1.1.6.2 Orta d\u0259r\u0259c\u0259li klinik t\u0259zah\u00fcr, I-II d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 31-60 1 il <\/p>\n\n\n\n

1.1.6.3 A\u011f\u0131r d\u0259r\u0259c\u0259li klinik t\u0259zah\u00fcr, II-III d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259, f\u0259sadla\u015fmalar v\u0259\/v\u0259 ya dig\u0259r orqanlar\u0131n kombin\u0259 edilmi\u015f z\u0259d\u0259l\u0259nm\u0259l\u0259ri il\u0259 70-80 2 il <\/p>\n\n\n\n

1.1.7 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n bakterioloji v\u0259 histoloji t\u0259sdiq edilmi\u015f v\u0259r\u0259mi A15 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n bakterioloji v\u0259 ya histoloji t\u0259sdiq edilm\u0259mi\u015f v\u0259r\u0259mi A16 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.7.1 I d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 aktivliyin solmas\u0131 m\u0259rh\u0259l\u0259sind\u0259 t\u0259n\u0259ff\u00fcs orqanlar\u0131 v\u0259r\u0259mi (sovurulma, qal\u0131nla\u015fma, bo\u015flu\u011fun \u00e7ap\u0131qla\u015fmas\u0131) 10-30 1 il <\/p>\n\n\n\n

1.1.7.2 I-II d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 aktivliyin solmas\u0131 m\u0259rh\u0259l\u0259sind\u0259 t\u0259n\u0259ff\u00fcs orqanlar\u0131 v\u0259r\u0259mi (sovurulma, qal\u0131nla\u015fma, bo\u015flu\u011fun \u00e7ap\u0131qla\u015fmas\u0131) 31-60 1 il <\/p>\n\n\n\n

1.1.7.3 III d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 aktivliyin solmas\u0131 m\u0259rh\u0259l\u0259sind\u0259 t\u0259n\u0259ff\u00fcs orqanlar\u0131 v\u0259r\u0259mi (sovurulma, qal\u0131nla\u015fma, bo\u015flu\u011fun \u00e7ap\u0131qla\u015fmas\u0131) 61-80 2 il<\/p>\n\n\n\n

1.1.7.4 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n aktiv v\u0259r\u0259mi (infiltrasiya, da\u011f\u0131lma, yay\u0131lma m\u0259rh\u0259l\u0259si, MBT+ v\u0259 ya MBT-) 81-90 2 il <\/p>\n\n\n\n

1.1.7.5 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n aktiv v\u0259r\u0259mi (infiltrasiya, da\u011f\u0131lma, s\u0259p\u0259l\u0259nm\u0259 m\u0259rh\u0259l\u0259si, MBT+ v\u0259 ya MBT-, a\u011f\u0131r d\u0259r\u0259c\u0259li intoksikasiya simptomlar\u0131n\u0131n m\u00fch\u00fcm t\u0259zah\u00fcr\u00fc, kaxeksiya, anemiya, amiloidoz, a\u011f ciy\u0259r \u00fcr\u0259yi, A\u00dc\u00c7 II-III d\u0259r\u0259c\u0259) 90-100 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

1.1.8 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n v\u0259r\u0259minin v\u0259 d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f v\u0259r\u0259min qal\u0131q f\u0259sadlar\u0131 B90.9 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.8.1 I d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan t\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n v\u0259r\u0259minin v\u0259 d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f v\u0259r\u0259min gecikmi\u015f f\u0259sadlar\u0131 (fibroz, fibrozlu-ocaql\u0131, bulloz-distrofik, kalsinatlar, plevropnevmoskleroz, sirroz, c\u0259rrahi m\u00fcdaxil\u0259 n\u0259tic\u0259l\u0259ri) 10-30 1 il <\/p>\n\n\n\n

1.1.8.2 II d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan t\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n v\u0259r\u0259minin v\u0259 d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f v\u0259r\u0259min gecikmi\u015f f\u0259sadlar\u0131 (fibroz, fibrozlu-ocaql\u0131, bulloz-distrofik, kalsinatlar, plevropnevmoskleroz, sirroz, c\u0259rrahi m\u00fcdaxil\u0259 n\u0259tic\u0259l\u0259ri) 31-60 1 il<\/p>\n\n\n\n

1.1.8.3 III d\u0259r\u0259c\u0259 xroniki t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan t\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n v\u0259r\u0259minin v\u0259 d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f v\u0259r\u0259min 80-90 M\u00fcdd\u0259tsiz 13 gecikmi\u015f f\u0259sadlar\u0131 (fibroz, fibrozlu-ocaql\u0131, bulloz-distrofik, kalsinatlar, plevropnevmoskleroz, sirroz, c\u0259rrahi m\u00fcdaxil\u0259 n\u0259tic\u0259l\u0259ri) <\/p>\n\n\n\n

1.1.9 MBT-n\u0131n olmas\u0131 v\u0259 ya olmamas\u0131 il\u0259 dig\u0259r orqanlar\u0131n v\u0259r\u0259mi A17-A19 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.9.1 Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyalar\u0131n\u0131n davaml\u0131 az \u0259h\u0259miyy\u0259tli pozulmas\u0131 il\u0259 m\u00fcxt\u0259lif lokalizasiyal\u0131 aktivliyi itirilmi\u015f v\u0259r\u0259m 10-30 1 il <\/p>\n\n\n\n

1.1.9.2 Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyalar\u0131n\u0131n davaml\u0131 m\u00fclayim pozulmas\u0131 il\u0259 m\u00fcxt\u0259lif lokalizasiyal\u0131 aktivliyi itirilmi\u015f v\u0259r\u0259m 31-60 1 il<\/p>\n\n\n\n

1.1.9.3 Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyalar\u0131n\u0131n davaml\u0131 t\u0259zah\u00fcr ed\u0259n pozulmas\u0131 il\u0259 m\u00fcxt\u0259lif lokalizasiyal\u0131 aktivliyi itirilmi\u015f v\u0259r\u0259m 61-80 2 il <\/p>\n\n\n\n

1.1.9.4 M\u00fcxt\u0259lif lokalizasiyal\u0131 aktiv v\u0259r\u0259m (infiltrasiya, da\u011f\u0131lma m\u0259rh\u0259l\u0259si, fistulalar\u0131n olmas\u0131) 81-90 2 il<\/p>\n\n\n\n

1.1.9.5 Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyalar\u0131n\u0131n davaml\u0131 \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 t\u0259zah\u00fcr ed\u0259n pozulmas\u0131 il\u0259 m\u00fcxt\u0259lif lokalizasiyal\u0131 aktivliyi itirilmi\u015f v\u0259r\u0259m 90-100 M\u00fcdd\u0259tsiz<\/p>\n\n\n\n

1.1.10 M\u0259rk\u0259zi sinir sistemi v\u0259r\u0259minin qal\u0131q f\u0259sadlar\u0131 B90.0 Sidik cinsiyy\u0259t orqanlar\u0131n\u0131n v\u0259r\u0259minin qal\u0131q f\u0259sadlar\u0131 B90.1 S\u00fcm\u00fck v\u0259 oynaq v\u0259r\u0259minin qal\u0131q f\u0259sadlar\u0131 B90.2 Dig\u0259r d\u0259qiql\u0259\u015fdirilmi\u015f orqanlar\u0131n v\u0259r\u0259minin qal\u0131q f\u0259sadlar\u0131 B90.8 T\u0259n\u0259ff\u00fcs orqanlar\u0131n\u0131n v\u0259r\u0259mi v\u0259 d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f v\u0259r\u0259min qal\u0131q f\u0259sadlar\u0131 B90.9 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

1.1.10.1 M\u00fcxt\u0259lif orqan v\u0259 sisteml\u0259rin v\u0259r\u0259minin m\u00fcalic\u0259d\u0259n sonrak\u0131 qal\u0131q \u0259lam\u0259tl\u0259ri. Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyas\u0131n\u0131n davaml\u0131 az d\u0259r\u0259c\u0259d\u0259 pozulmas\u0131. 10-30 1 il 14 1.1.10.2 M\u00fcxt\u0259lif orqan v\u0259 sisteml\u0259rin v\u0259r\u0259minin m\u00fcalic\u0259d\u0259n sonrak\u0131 qal\u0131q \u0259lam\u0259tl\u0259ri. Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyas\u0131n\u0131n davaml\u0131 m\u00fclayim pozulmas\u0131. 31-60 1 il <\/p>\n\n\n\n

1.1.10.3 M\u00fcxt\u0259lif orqan v\u0259 sisteml\u0259rin v\u0259r\u0259minin m\u00fcalic\u0259d\u0259n sonrak\u0131 qal\u0131q \u0259lam\u0259tl\u0259ri. Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyas\u0131n\u0131n t\u0259zah\u00fcr ed\u0259n d\u0259r\u0259c\u0259d\u0259 pozulmas\u0131. 61-80 2 il<\/p>\n\n\n\n

1.1.10.4 M\u00fcxt\u0259lif orqan v\u0259 sisteml\u0259rin v\u0259r\u0259minin m\u00fcalic\u0259d\u0259n sonrak\u0131 gecikmi\u015f \u0259lam\u0259tl\u0259ri. Z\u0259d\u0259l\u0259nmi\u015f orqan v\u0259 sisteml\u0259rin funksiyas\u0131n\u0131n davaml\u0131 \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 t\u0259zah\u00fcr ed\u0259n pozulmas\u0131. 81-100 M\u00fcdd\u0259tsiz<\/p>\n\n\n\n

2.Qan d\u00f6vran\u0131 sisteminin x\u0259st\u0259likl\u0259ri (I00-I99) 2-ci b\u0259nd\u0259 dair qeyd: X\u0259st\u0259likl\u0259rd\u0259n, travman\u0131n n\u0259tic\u0259l\u0259ri v\u0259 ya \u00e7at\u0131\u015fmazl\u0131qlardan ir\u0259li g\u0259l\u0259n insan orqanizminin qan d\u00f6vran\u0131 sisteminin davaml\u0131 pozuntular\u0131n\u0131n a\u011f\u0131rl\u0131q d\u0259r\u0259c\u0259sinin k\u0259miyy\u0259tc\u0259 qiym\u0259tl\u0259ndirilm\u0259si klinik-funksional t\u0259zah\u00fcrl\u0259rin ifad\u0259 d\u0259r\u0259c\u0259sinin qiym\u0259tl\u0259dirilm\u0259sin\u0259 \u0259saslan\u0131r: A\u011fr\u0131 sindromu-kardialgiya v\u0259 ya stenokardiya, hipertonik sindrom, a\u011fciy\u0259r hipertenziyas\u0131, \u00fcr\u0259k ritminin pozuntusu, bay\u0131lma v\u0259ziyy\u0259tl\u0259ri, qan d\u00f6vran\u0131 \u00e7at\u0131\u015fmazl\u0131qlar\u0131. Patoloji prosesin dig\u0259r amill\u0259ri d\u0259 n\u0259z\u0259r\u0259 al\u0131n\u0131r: gedi\u015fat\u0131n formas\u0131 v\u0259 a\u011f\u0131rl\u0131\u011f\u0131, prosesin aktivliyi, k\u0259skinl\u0259\u015fm\u0259l\u0259rin olmas\u0131 v\u0259 tezliyi, patoloji prosesin yay\u0131lmas\u0131, h\u0259d\u0259f orqanlar\u0131n qo\u015fulmas\u0131, immunitetin azald\u0131lmas\u0131na ehtiyac, f\u0259sadlar\u0131n olmas\u0131.<\/p>\n\n\n\n

2.1 Qan t\u0259zyiqinin y\u00fcks\u0259k olmas\u0131 il\u0259 s\u0259ciyy\u0259l\u0259n\u0259n x\u0259st\u0259likl\u0259r I10-I<\/p>\n\n\n\n

2.1.1 Essensial birincili hipertenziya I10 \u00dcr\u0259yin hipertenziv x\u0259st\u0259liyi I11 \u018fsas\u0259n b\u00f6yr\u0259kl\u0259rin z\u0259d\u0259l\u0259nm\u0259si il\u0259 m\u00fc\u015fayi\u0259t olunan hipertenziv hipertoniya x\u0259st\u0259liyi I12 \u018fsas\u0259n \u00fcr\u0259yin v\u0259 b\u00f6yr\u0259kl\u0259rin z\u0259d\u0259l\u0259nm\u0259si il\u0259 m\u00fc\u015fayi\u0259t olunan hipertenziv hipertoniya x\u0259st\u0259liyi I13 \u0130kincili hipertenziya I15 Renovaskulyar hipertenziya I15.0 B\u00f6yr\u0259yin dig\u0259r z\u0259d\u0259l\u0259nm\u0259l\u0259rin\u0259 g\u00f6r\u0259 ikincili hipertenziya I15.1 Endokrin pozuntulara g\u00f6r\u0259 ikincili hipertenziya I15.2 Dig\u0259r ikincili hipertenziya I15.8 D\u0259qiql\u0259\u015fdirilm\u0259mi\u015f ikincili hipertenziya I15.9 15 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

2.1.1.1 I d\u0259r\u0259c\u0259li arterial hipertenziya, x\u0259st\u0259liyin birinci m\u0259rh\u0259l\u0259si orqanizmin funksiyas\u0131(lar)n\u0131n az \u0259h\u0259miyy\u0259tli pozuntusu zaman\u0131; arterial hipertenziyan\u0131n 1 v\u0259 2-ci d\u0259r\u0259c\u0259si, x\u0259st\u0259liyin ikinci m\u0259rh\u0259l\u0259si, h\u0259d\u0259f orqanlar\u0131n (\u00fcr\u0259k, qan damarlar\u0131, torlu qi\u015fa, beyin, b\u00f6yr\u0259kl\u0259r) funksiyalar\u0131n\u0131n az \u0259h\u0259miyy\u0259tli pozulmas\u0131 il\u0259 z\u0259d\u0259l\u0259nm\u0259si; y\u00fcng\u00fcl v\u0259\/v\u0259 ya nadir ba\u015f ver\u0259n (ild\u0259 1-2 d\u0259f\u0259) krizl\u0259r zaman\u0131. 10-30 1 il<\/p>\n\n\n\n

2.1.1.2 Arterial hipertenziyan\u0131n 1, 2 v\u0259 3-c\u00fc d\u0259r\u0259c\u0259l\u0259ri, x\u0259st\u0259liyin ikinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc m\u0259rh\u0259l\u0259l\u0259ri, h\u0259d\u0259f orqanlar\u0131n\u0131n z\u0259d\u0259l\u0259nm\u0259si v\u0259\/v\u0259 ya \u0259laq\u0259li x\u0259st\u0259likl\u0259rd\u0259n (\u00fcr\u0259yin i\u015femik x\u0259st\u0259liyi, xroniki \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, beyin qan d\u00f6vran\u0131n\u0131n pozulmas\u0131, hipertonik ensefalopatiya, damar demensiyas\u0131, qabar\u0131q hipertonik retinopatiya, xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 arteriyalar\u0131n okkl\u00fczion x\u0259st\u0259liyi — \u0259n az bir b\u00f6y\u00fck arteriyada n\u0259bzin olmamas\u0131 arxa ayaq arteriyas\u0131ndan ba\u015fqa, aorta anevrizmas\u0131) orqanizmin funksiyas\u0131(lar)n\u0131n m\u00fclayim pozulmas\u0131; orta a\u011f\u0131r orta tezlikl\u0259 ba\u015f ver\u0259n (ild\u0259 3-5 d\u0259f\u0259) v\u0259 ya nadir olan (ild\u0259 1-2 d\u0259f\u0259) a\u011f\u0131r krizl\u0259r oldu\u011fu zaman 31-60 1 il <\/p>\n\n\n\n

2.1.1.3 Arterial hipertenziyan\u0131n 1,2 v\u0259 3-c\u00fc d\u0259r\u0259c\u0259l\u0259ri, x\u0259st\u0259liyin \u00fc\u00e7\u00fcnc\u00fc m\u0259rh\u0259l\u0259l\u0259ri, \u0259laq\u0259li klinik v\u0259ziyy\u0259tl\u0259rd\u0259n ir\u0259li g\u0259l\u0259n orqanizmin funksiyas\u0131(lar)n\u0131n t\u0259zah\u00fcr ed\u0259n pozulmas\u0131, orta a\u011f\u0131r tez-tez (ild\u0259 6 d\u0259f\u0259d\u0259n \u00e7ox) ba\u015f ver\u0259n v\u0259 ya orta tezlikl\u0259 (ild\u0259 3-5 d\u0259f\u0259) olan a\u011f\u0131r krizl\u0259r oldu\u011fu zaman 61-80 1 il <\/p>\n\n\n\n

2.1.1.4 Arterial hipertenziyan\u0131n 1, 2 v\u0259 3-c\u00fc d\u0259r\u0259c\u0259l\u0259ri, x\u0259st\u0259liyin ikinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc m\u0259rh\u0259l\u0259l\u0259ri, \u0259laq\u0259li klinik v\u0259ziyy\u0259tl\u0259rd\u0259n ir\u0259li g\u0259l\u0259n orqanizmin funksiyas\u0131(lar)n\u0131n \u0259h\u0259miyy\u0259tli t\u0259zah\u00fcr ed\u0259n pozulmas\u0131, tez-tez (ild\u0259 6 d\u0259f\u0259d\u0259n \u00e7ox) olan a\u011f\u0131r krizl\u0259r oldu\u011fu zaman 81-100 2 il <\/p>\n\n\n\n

2.2 \u00dcr\u0259yin i\u015femik x\u0259st\u0259liyi I20-I25 16 2.2.1 Stenokardiya [d\u00f6\u015f ina\u011f\u0131] I20 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

2.2.1.1 Stenokardiya I FS — latent, \u00fcr\u0259k qan d\u00f6vran\u0131n\u0131n az \u0259h\u0259miyy\u0259tli pozuntusu (I m\u0259rh\u0259l\u0259 X\u00dc\u00c7 il\u0259 m\u00fc\u015fayi\u0259t olunanda) 10-20 1 il <\/p>\n\n\n\n

2.2.1.2 Stenokardiya II FS — y\u00fcng\u00fcl, \u00fcr\u0259k qan d\u00f6vran\u0131n\u0131n m\u00fclayim pozuntusu (I m\u0259rh\u0259l\u0259 X\u00dc\u00c7 il\u0259 m\u00fc\u015fayi\u0259t olunanda) 30 1 il <\/p>\n\n\n\n

2.2.1.3 Stenokardiya III FS — orta a\u011f\u0131r, \u00fcr\u0259k qan d\u00f6vran\u0131n\u0131n t\u0259zah\u00fcr ed\u0259n pozuntusu (IIA m\u0259rh\u0259l\u0259 X\u00dc\u00c7 il\u0259 m\u00fc\u015fayi\u0259t olunanda) 31-60 1 il <\/p>\n\n\n\n

2.2.1.4 Stenokardiya III FS — orta a\u011f\u0131r, \u00fcr\u0259k qan d\u00f6vran\u0131n\u0131n t\u0259zah\u00fcr ed\u0259n pozuntusu (IIB m\u0259rh\u0259l\u0259 X\u00dc\u00c7 il\u0259 m\u00fc\u015fayi\u0259t olunanda) 61-80 1 il <\/p>\n\n\n\n

2.2.1.5 Stenokardiya \u0130V FS — a\u011f\u0131r, \u00fcr\u0259k qan d\u00f6vran\u0131n\u0131n \u0259h\u0259miyy\u0259tli pozuntusu (III m\u0259rh\u0259l\u0259 X\u00dc\u00c7 il\u0259 m\u00fc\u015fayi\u0259t olunanda) 81-100 M\u00fcdd\u0259tsiz<\/p>\n\n\n\n

2.2.2 \u00dcr\u0259yin xroniki i\u015femik x\u0259st\u0259liyi I25 \u018fvv\u0259ll\u0259r ke\u00e7iril\u0259n miokard infarkt\u0131 I25.2 \u00dcr\u0259k anevrizmas\u0131 I25.3 Miokard\u0131n simptomsuz i\u015femiyas\u0131 I25.6 Qiym\u0259tl\u0259ndirm\u0259<\/p>\n\n\n\n

2.2.2.1 Funskiyalar\u0131n \u0259h\u0259miyy\u0259tsiz pozulmas\u0131 — stenokardiya I FS; \u00fcr\u0259k ritminin az \u0259h\u0259miyy\u0259tli davaml\u0131 v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131; fiziki y\u00fckl\u0259m\u0259y\u0259 d\u00f6z\u00fcl\u0259 bil\u0259n halda I FS-\u0259 uy\u011fun olan miokard\u0131n simptomsuz (a\u011fr\u0131s\u0131z) i\u015femiyas\u0131 v\u0259 EKQ monitorinqinin n\u0259tic\u0259l\u0259rin\u0259 g\u00f6r\u0259 miokard\u0131n a\u011fr\u0131s\u0131z i\u015femiyas\u0131 epizodlar\u0131n\u0131n toplam g\u00fcnd\u0259lik m\u00fcdd\u0259ti 10 d\u0259qiq\u0259d\u0259n az olduqda; X\u00dc\u00c7 I m\u0259rh\u0259l\u0259 10-30 1 il <\/p>\n\n\n\n

2.2.2.2 Funskiyalar\u0131n m\u00fclayim pozulmas\u0131 — stenokardiya II FS; \u00fcr\u0259k ritminin m\u00fclayim daimi v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131; II FS-\u0259 aid v\u0259 d\u00f6z\u00fcl\u0259 bil\u0259n fiziki y\u00fckl\u0259m\u0259 zaman\u0131 miokard\u0131n simptomsuz (a\u011fr\u0131s\u0131z) i\u015femiyas\u0131 v\u0259 EKQ monitorinqinin n\u0259tic\u0259l\u0259rin\u0259 g\u00f6r\u0259 miokard\u0131n a\u011fr\u0131s\u0131z i\u015femiyas\u0131 epizodlar\u0131n\u0131n toplam g\u00fcnd\u0259lik m\u00fcdd\u0259ti 11-39 d\u0259qiq\u0259 interval\u0131nda olduqda; X\u00dc\u00c7 IIA m\u0259rh\u0259l\u0259 31-60 1 il <\/p>\n\n\n\n

2.2.2.3 Funksiyalar\u0131n t\u0259zah\u00fcr ed\u0259n pozulmas\u0131 — stenokardiya III FS; \u00fcr\u0259k ritminin t\u0259zah\u00fcr ed\u0259n daimi v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131; \u00fcr\u0259kdaxili trombozla postinfarkt anevrizma; III- FS-\u0259 aid v\u0259 d\u00f6z\u00fcl\u0259 bil\u0259n fiziki y\u00fckl\u0259m\u0259 zaman\u0131 miokard\u0131n simptomsuz (a\u011fr\u0131s\u0131z) i\u015femiyas\u0131 v\u0259 EKQ monitorinqinin n\u0259tic\u0259l\u0259rin\u0259 g\u00f6r\u0259 miokard\u0131n a\u011fr\u0131s\u0131z i\u015femiyas\u0131 epizodlar\u0131n\u0131n toplam g\u00fcnd\u0259lik m\u00fcdd\u0259ti 40-59 d\u0259qiq\u0259 interval\u0131nda olduqda; X\u00dc\u00c7 IIB m\u0259rh\u0259l\u0259 61-80 1 il <\/p>\n\n\n\n

2.2.2.4 Funksiyalar\u0131n \u0259h\u0259miyy\u0259tli t\u0259zah\u00fcr ed\u0259n pozulmas\u0131 — stenokardiya IV FS; \u00fcr\u0259k ritminin \u0259h\u0259miyy\u0259tli t\u0259zah\u00fcr ed\u0259n daimi v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131; \u00fcr\u0259kdaxili trombozla postinfarkt anevrizma; IV- FS-\u0259 aid v\u0259 d\u00f6z\u00fcl\u0259 bil\u0259n fiziki y\u00fckl\u0259m\u0259 zaman\u0131 miokard\u0131n simptomsuz (a\u011fr\u0131s\u0131z) i\u015femiyas\u0131 v\u0259 EKQ monitorinqinin n\u0259tic\u0259l\u0259rin\u0259 g\u00f6r\u0259 miokard\u0131n a\u011fr\u0131s\u0131z i\u015femiyas\u0131 epizodlar\u0131n\u0131n toplam g\u00fcnd\u0259lik m\u00fcdd\u0259ti 60 d\u0259qiq\u0259 v\u0259 daha \u00e7ox olduqdan, X\u00dc\u00c7 III m\u0259rh\u0259l\u0259 81-100 M\u00fcdd\u0259tsiz 2.2.3 Dilatasion kardiomiopatiya I42 Qiym\u0259tl\u0259ndirm\u0259<\/p>\n\n\n\n

2.2.3.1 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n \u0259h\u0259miyy\u0259tsiz (az \u0259h\u0259miyy\u0259tli) pozulmas\u0131 -y\u00fcng\u00fcl kardiomeqaliya, \u00fcr\u0259k ritminin az \u0259h\u0259miyy\u0259tli davaml\u0131 v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131, trombemboliya a\u011f\u0131rla\u015fmalar\u0131n\u0131n olmamas\u0131, \u00fcr\u0259yin qlobal funksiyas\u0131n\u0131n, koronar qan d\u00f6vran\u0131 v\u0259 beyin hemodinamikas\u0131n\u0131n \u0259h\u0259miyy\u0259tsiz pozulmas\u0131 10-30 1il<\/p>\n\n\n\n

2.2.3.2 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n m\u00fclayim pozulmas\u0131-orta d\u0259r\u0259c\u0259li kardiomeqaliya, \u00fcr\u0259k ritminin m\u00fclayim davaml\u0131 v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131, trombemboliya a\u011f\u0131rla\u015fmalar\u0131n\u0131n olmamas\u0131, \u00fcr\u0259yin qlobal funksiyas\u0131n\u0131n, koronar qan d\u00f6vran\u0131 v\u0259 beyin hemodinamikas\u0131n\u0131n m\u00fclayim pozulmas\u0131, \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 II FS 31-60 3 il<\/p>\n\n\n\n

2.2.3.3 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n t\u0259zah\u00fcr ed\u0259n pozulmas\u0131- orta d\u0259r\u0259c\u0259li kardiomeqaliya, \u00fcr\u0259k ritminin t\u0259zah\u00fcr ed\u0259n davaml\u0131 61-80 M\u00fcdd\u0259tsiz 18 v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131, trombemboliya a\u011f\u0131rla\u015fmalar\u0131n\u0131n olmas\u0131, \u00fcr\u0259yin qlobal funsiyas\u0131n\u0131n, koronar qan d\u00f6vran\u0131 v\u0259 beyin hemodinamikas\u0131n\u0131n t\u0259zah\u00fcr ed\u0259n pozulmas\u0131, \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 III FS <\/p>\n\n\n\n

2.2.3.4 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 t\u0259zah\u00fcr ed\u0259n pozulmas\u0131 — orta d\u0259r\u0259c\u0259li kardiomeqaliya, \u00fcr\u0259k ritminin t\u0259zah\u00fcr ed\u0259n davaml\u0131 v\u0259\/v\u0259 ya paroksizmal pozulmas\u0131, trombemboliya a\u011f\u0131rla\u015fmalar\u0131n\u0131n olmas\u0131, \u00fcr\u0259yin qlobal funksiyas\u0131n\u0131n, koronar qan d\u00f6vran\u0131 v\u0259 beyin hemodinamikas\u0131n\u0131n \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 t\u0259zah\u00fcr ed\u0259n pozulmas\u0131, \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 III FS 90-100 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

2.2.4 \u00dcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 I50 Dur\u011funluq \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 I50.0 Sol m\u0259d\u0259cik \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 I50.1 D\u0259qiql\u0259\u015fdirilm\u0259mi\u015f \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 I50.9 Qiym\u0259tl\u0259ndirm\u0259 <\/p>\n\n\n\n

2.2.4.1 X\u00dc\u00c7 I m\u0259rh\u0259l\u0259, I-II FS — qan d\u00f6vran\u0131 funksiyas\u0131n\u0131n pozulmas\u0131 \u0259h\u0259miyy\u0259tsizdir 10-30 1 il <\/p>\n\n\n\n

2.2.4.2 X\u00dc\u00c7 IIA m\u0259rh\u0259l\u0259, II-III FS — qan d\u00f6vran\u0131 funksiyas\u0131n\u0131n pozulmas\u0131 m\u00fclayimdir 31-60 1 il <\/p>\n\n\n\n

2.2.4.3 X\u00dc\u00c7 IIB m\u0259rh\u0259l\u0259, III-IV FS — qan d\u00f6vran\u0131 funksiyas\u0131n\u0131n pozulmas\u0131 t\u0259zah\u00fcr ed\u0259ndir 61-80 1 il <\/p>\n\n\n\n

2.2.4.4 X\u00dc\u00c7 III m\u0259rh\u0259l\u0259, IV FS — qan d\u00f6vran\u0131 funksiyas\u0131n\u0131n pozulmas\u0131 \u0259h\u0259miyy\u0259tlidir 81-100 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

2.2.5 \u00dcr\u0259k v\u0259 damar implantantlar\u0131n\u0131n v\u0259 transplantantlar\u0131n\u0131n olmas\u0131 Z95 S\u00fcni \u00fcr\u0259k ritmi apar\u0131c\u0131s\u0131n\u0131n olmas\u0131 Z95.0 Aortokoronar \u015funtlu transplantat\u0131n olmas\u0131 Z95.1 \u00dcr\u0259k qapa\u011f\u0131n\u0131n protezinin olmas\u0131 Z95.2 Ksenogen \u00fcr\u0259k qapa\u011f\u0131n\u0131n olmas\u0131 Z95.3 \u00dcr\u0259k qapa\u011f\u0131n\u0131n dig\u0259r \u0259v\u0259zedicisinin olmas\u0131 Z95.4 19 Koronar angioplastik implantat\u0131n v\u0259 transplantat\u0131n olmas\u0131 Z95.5 Dig\u0259r \u00fcr\u0259k v\u0259 damar implantatlar\u0131n v\u0259 transplantatlar\u0131n olmas\u0131 Z95.8 D\u0259qiql\u0259\u015fdirilm\u0259mi\u015f \u00fcr\u0259k v\u0259 damar implantat\u0131n\u0131n v\u0259 transplantat\u0131n olmas\u0131 Z95.9 Postkardiotomik sindrom \u013097.0 \u00dcr\u0259k \u00fcz\u0259rind\u0259 apar\u0131lan c\u0259rrahi \u0259m\u0259liyyatlardan sonra ba\u015f ver\u0259n dig\u0259r funksional pozuntular \u013097.1 Qiym\u0259tl\u0259ndirm\u0259<\/p>\n\n\n\n

2.2.5.1 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n \u0259h\u0259miyy\u0259tsiz pozulmas\u0131na (I d\u0259r\u0259c\u0259) g\u0259tir\u0259n (X\u00dc\u00c7 I m\u0259rh\u0259l\u0259, I-II FS) 30 1 il 2.2.5.2 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n m\u00fclayim pozulmas\u0131na (II d\u0259r\u0259c\u0259) g\u0259tir\u0259n (X\u00dc\u00c7 IIA m\u0259rh\u0259l\u0259, II-III FS) 31-60 1il 2.2.5.3 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n t\u0259zah\u00fcr ed\u0259n pozulmas\u0131na (III d\u0259r\u0259c\u0259) g\u0259tir\u0259n (X\u00dc\u00c7 IIB m\u0259rh\u0259l\u0259, III-IV FS) 61-80 1 il <\/p>\n\n\n\n

2.2.5.4 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n \u0259h\u0259miyy\u0259tli t\u0259zah\u00fcr ed\u0259n pozulmas\u0131na (IV d\u0259r\u0259c\u0259) g\u0259tir\u0259n (X\u00dc\u00c7 III m\u0259rh\u0259l\u0259, IV FS) 81-100 M\u00fcdd\u0259tsiz<\/p>\n\n\n\n

2.2.6 Transplantasiya olunmu\u015f \u00fcr\u0259yin olmas\u0131 Z94.1 Transplantasiya olunmu\u015f \u00fcr\u0259k v\u0259 a\u011f ciy\u0259rin olmas\u0131 Z94.3 Qiym\u0259tl\u0259ndirm\u0259<\/p>\n\n\n\n

2.2.6.1 \u00dcr\u0259yin k\u00f6\u00e7\u00fcr\u00fclm\u0259sind\u0259n sonrak\u0131 v\u0259ziyy\u0259t ilk 2 il \u0259rzind\u0259 100 2 il <\/p>\n\n\n\n

2.2.6.2 \u00dcr\u0259yin k\u00f6\u00e7\u00fcr\u00fclm\u0259sind\u0259n sonrak\u0131 v\u0259ziyy\u0259t 2 illik m\u00fc\u015fahid\u0259d\u0259n sonra immunitetin z\u0259ifl\u0259dilm\u0259sin\u0259 v\u0259\/v\u0259 ya orqanizmin sisteml\u0259rinin sistematik m\u00fcalic\u0259 edilm\u0259sin\u0259 olan ehtiyacla 80 M\u00fcdd\u0259tsiz <\/p>\n\n\n\n

2.2.7 \u00dcr\u0259yin dig\u0259r travmalar\u0131 S26.8 \u00dcr\u0259yin d\u0259qiql\u0259\u015fdirilm\u0259mi\u015f travmas\u0131 S26.9 Qiym\u0259tl\u0259ndirm\u0259<\/p>\n\n\n\n

2.2.7.1 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n \u0259h\u0259miyy\u0259tsiz pozulmas\u0131na (I d\u0259r\u0259c\u0259) g\u0259tir\u0259n (X\u00dc\u00c7 I m\u0259rh\u0259l\u0259, I-II FS) 40 1il <\/p>\n\n\n\n

2.2.7.2 \u00dcr\u0259k-damar sisteminin funksiyalar\u0131n\u0131n m\u00fclayim pozulmas\u0131na (II d\u0259r\u0259c\u0259) g\u0259tir\u0259n (X\u00dc\u00c7 IIA m\u0259rh\u0259l\u0259, II-III FS) 40-60 1il <\/p>\n\n\n\n

Davam ed\u0259c\u0259k…<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Bu i\u015fi \u018fm\u0259k v\u0259 \u0259halinin sosial m\u00fcdafi\u0259si nazirliyi g\u00f6rm\u0259liydi. Sosial maarifl\u0259ndirm\u0259 rubrikas\u0131 il\u0259 30 il m\u00fcharib\u0259 aparm\u0131\u015f \u00f6lk\u0259d\u0259 \u0259lilliyin t\u0259yinat\u0131yla ba\u011fl\u0131 \u00abm\u00fcharib\u0259\u00bb ad\u0131n\u0131n \u00e7\u0259kilm\u0259m\u0259si<\/p>\n","protected":false},"author":2,"featured_media":42274,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-42271","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sosial"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/posts\/42271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/fedai.az\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42271"}],"version-history":[{"count":5,"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/posts\/42271\/revisions"}],"predecessor-version":[{"id":42283,"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/posts\/42271\/revisions\/42283"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fedai.az\/index.php?rest_route=\/wp\/v2\/media\/42274"}],"wp:attachment":[{"href":"https:\/\/fedai.az\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fedai.az\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fedai.az\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}